FDA Grants Accelerated Approval to Etcamah + CDK4/6 Inhibitors for ESR1‑Mutant Advanced HR‑Positive, HER2‑Negative Breast Cancer

The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adults with HR‑positive, HER2‑negative advanced breast cancer when an ESR1 mutation em...



























